Booster vaccines reduced the risk of COVID‑19–related hospitalization and death, according to a new study of over 3 million ...

Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million ...

COVID-19 vaccination showed effectiveness in reducing hospitalizations and severe disease outcomes associated with the SARS-CoV-2 JN.1 lineage, according to a recent study published in JAMA Network ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Updated 2024-2025 COVID-19 vaccines significantly reduced the risk for hospitalization and severe outcomes despite the emergence of new viral lineages.

By Hugo Francisco de Souza A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID ...

A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of ...

Fact Check - A former Pfizer vice president's claim that the Covid-19 pandemic does not exist contradicts scientific facts.

Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...

Novavax Inc (NVAX) reports a 65% revenue increase and secures major partnerships, despite facing regulatory uncertainties and strategic challenges.

Scientists say they have uncovered why a small number of people developed a rare blood clotting condition after receiving ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...